FDA
-
-
-
-
-
-
-
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
-
-
-
-
-
-
-
Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

